A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown ... the high-dose group achieved an average weight loss of 20.7%, compared to 17.5% with the ...

It also suppresses appetite and boosts feelings of fullness, which can then lead to reduced food intake and potential weight loss. Ozempic, Wegovy, and compounded semaglutide are once-weekly ...

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

Four years after starting semaglutide, patients maintained an average weight loss of 10% of their body weight, a peer-reviewed 2024 study funded by Novo Nordisk found. Doctors say the drug’s ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Experts say it’s not yet clear how safe these drugs are for people who don’t need to lose weight ... the semaglutide group drank roughly half the amount, on average, compared to those who ...